Review concluded regarding general reimbursement for Zomig Nasal®

20 January 2012

The Danish Medicines Agency has completed its review of an application for general reimbursement for Zomig Nasal®. The product has been granted general reimbursement.

Zomig Nasal® is indicated for the acute treatment of migraine.

When we compare Zomig Nasal® with other similar medicines, we assess that the price of the medicine is commensurate with its therapeutic value.

The reimbursement status of Zomig Nasal® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.

Find the Danish Medicines Agency's decision in the box to the right (in Danish only).

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.